1. Home
  2. ENTO vs TRNR Comparison

ENTO vs TRNR Comparison

Compare ENTO & TRNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTO
  • TRNR
  • Stock Information
  • Founded
  • ENTO 2014
  • TRNR 2017
  • Country
  • ENTO United States
  • TRNR United States
  • Employees
  • ENTO N/A
  • TRNR N/A
  • Industry
  • ENTO Biotechnology: Pharmaceutical Preparations
  • TRNR Consumer Electronics/Appliances
  • Sector
  • ENTO Health Care
  • TRNR Technology
  • Exchange
  • ENTO Nasdaq
  • TRNR Nasdaq
  • Market Cap
  • ENTO 2.9M
  • TRNR 3.3M
  • IPO Year
  • ENTO 2016
  • TRNR 2023
  • Fundamental
  • Price
  • ENTO $0.49
  • TRNR $1.00
  • Analyst Decision
  • ENTO
  • TRNR
  • Analyst Count
  • ENTO 0
  • TRNR 0
  • Target Price
  • ENTO N/A
  • TRNR N/A
  • AVG Volume (30 Days)
  • ENTO 68.7K
  • TRNR 3.8M
  • Earning Date
  • ENTO 11-13-2024
  • TRNR 03-31-2025
  • Dividend Yield
  • ENTO N/A
  • TRNR N/A
  • EPS Growth
  • ENTO N/A
  • TRNR N/A
  • EPS
  • ENTO N/A
  • TRNR N/A
  • Revenue
  • ENTO N/A
  • TRNR $3,180,000.00
  • Revenue This Year
  • ENTO N/A
  • TRNR $1,543.45
  • Revenue Next Year
  • ENTO N/A
  • TRNR $54.84
  • P/E Ratio
  • ENTO N/A
  • TRNR N/A
  • Revenue Growth
  • ENTO N/A
  • TRNR 226.82
  • 52 Week Low
  • ENTO $0.19
  • TRNR $0.86
  • 52 Week High
  • ENTO $9.35
  • TRNR $4,760.00
  • Technical
  • Relative Strength Index (RSI)
  • ENTO 43.83
  • TRNR 16.61
  • Support Level
  • ENTO $0.45
  • TRNR $1.14
  • Resistance Level
  • ENTO $0.54
  • TRNR $2.17
  • Average True Range (ATR)
  • ENTO 0.06
  • TRNR 0.26
  • MACD
  • ENTO 0.00
  • TRNR -0.02
  • Stochastic Oscillator
  • ENTO 24.31
  • TRNR 10.57

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

About TRNR Interactive Strength Inc.

Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.

Share on Social Networks: